Protease inhibition in African subtypes of HIV-1

AIDS Reviews

Volumn 5, Issue 3, 2003, Pages 165-171

  Velázquez Campoy, Adrián ^a   Vega, Sonia ^a   Fleming, Erin ^a   Bacha, Usman ^a   Sayed, Yasien ^b   Dirr, Heini W ^b   Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Africa; AIDS; Calorimetry; Drug resistance; Non B subtypes; Protease inhibitors

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AFRICA; BINDING AFFINITY; BIOCHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PREVALENCE; REVIEW; VIRUS INHIBITION; VIRUS MUTATION; VIRUS TYPING;

DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION;

EID: 0242351943     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Cohen J. Ground Zero: AIDS research in Africa. Science 2000;288:2150-70.
2. Thomson M, Nájera RR. Travel and the introduction of HIV type 1 non-B subtype genetic forms into western countries. Travel Med 2001;32:1732-7.
3. Holguín A, Rodés B, Dietrich U, Soriano V. HIV type 1 subtypes circulating in Spain. J Med Virology 1999;59:189-93.
4. Holguín A, Álvarez A, Soriano V. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 2002;16:1163-70.
5. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson J, Eshleman S. Analysis of HIV-1 protease and reverse transcriptase in antiretroviral drug naive Ugandan adults. AIDS Res Hum Retroviruses 2000;16:807-13.
6. Brennan C, Lund J, Golden A, et al. Serological and phylogenetic characterization of HIV-1 subtypes in Uganda. AIDS 1997;11:1823-32.
7. Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998;12:1109-11.
8. Gulnik S, Suvorov L, Liu B, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995;34:9282-7.
9. Velázquez-Campoy A, Vega S, Freire E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 2002;41:8613-9.
10. Todd M, Semo N, Freire E. The structural stability of the HIV-1 protease. J Mol Biol 1998;283:475-88.
11. Todd M, Luque I, Velázquez-Campoy A, Freire E. The thermodynamic basis of resistance to HIV-1 protease inhibition. Calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 2000;39:11876-83.
12. Velázquez-Campoy A, Kiso Y, Freire E. The binding energetics of first and second generation HIV-1 protease inhibitors: Implications for drug design. Arch Biochim Biophys 2001;390:169-75.
13. Ohtaka H, Velázquez-Campoy A, Xie D, Freire E. Overcoming drug resistance in HIV-1 chemotherapy: The binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Science 2002;11:1908-16.
14. Velázquez-Campoy A, Todd M, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci USA 2001;98:6062-7.
15. Cane P, De Ruiter A, Rice P, Wiselka M, Fox R, Pillay D. Resistance-associated mutations in the HIV type 1 subtype-C protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol 2001;39:2652-4.
16. Kantor R, Zijenah L, Shafer R, et al. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Human Retroviruses 2002;18:1407-13.
17. Vergne L, Peeters M, Mpoundi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B HIV type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38:3919-25.
18. Pieniazek D, Rayfield M, Hu D, et al. Proteases sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. AIDS 2000;14:1489-95.
19. Ohtaka H, Schon A, Freire E. Multidrug-resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Submitted 2003.
20. Gulnik S, Erickson J, Xie D. HIV protease: Enzyme function and drug resistance. In: Litwack G, ed. Vitamins and Hormones. New York: Academic Press 1999.
21. Velázquez-Campoy A, Luque I, Todd M, Milutinovich M, Kiso Y, Freire E. Thermodynamic dissection of the binding energetics of KNI-272, a powerful HIV-1 protease inhibitor. Protein Science 2000;9:1801-9.